(Q33341524)

25 July 2017

title

Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study (English)

1 reference

25 July 2017

1 reference

Ewert Schulte-Frohlinde

4

object named as

Ewert Schulte-Frohlinde

0 references

author name string

Florian Eckel

1

1 reference

25 July 2017

Christian Lersch

2

1 reference

25 July 2017

Gerald Assmann

3

1 reference

25 July 2017

Ewert Schulte-Frohlinde

4

1 reference

25 July 2017

publication date

1 January 2002

1 reference

25 July 2017

1 reference

25 July 2017

volume

20

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

180-185

1 reference

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

Long-term outcome in patients with advanced hilar bile duct tumors undergoing palliative endoscopic or percutaneous drainage

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001144

21 January 2018

Identifiers

DOI

10.1081/CNV-120001144

1 reference

25 July 2017

1 reference